Indeed, breast cancer-derived EVs favor drug resistance by transferring pro-survival signals, reducing the intracellular accumulation of drugs, upregulating P-glycoprotein expression in sensitive cancer cells, and altering the epithelial–mesenchymal transition [33]. The gene discussed is ABCB1; the disease is breast carcinoma.